Reducing the levels of triglycerides and triglyceride-rich lipoproteins remains an unmet clinical need. Olezarsen is an antisense oligonucleotide targeting messenger RNA for apolipoprotein C-III ...

Ionis Pharmaceuticals has reported positive topline outcomes from the randomised, global Phase III Essence study of Tryngolza ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline results from the Essence study of olezarsen in ...

Olezarsen is a promising treatment for severe hypertriglyceridemia, familial chylomicronemia syndrome and other dyslipidemia.

Topline results from the Essence study show that olezarsen significantly lowered mean triglyceride levels compared to placebo ...

On a mission to expand its recently approved Tryngolza beyond the rare genetic disorder familial chylomicronemia syndrome ...

Expert Rev Cardiovasc Ther. 2011;9(8):987-997. © 2011 Expert Reviews Ltd. Cite this: Why, When and How Should Hypertriglyceridemia be Treated in the High-risk ...

Topline data were announced from a phase 3 trial evaluating olezarsen in patients with moderate hypertriglyceridemia with or at risk for ASCVD.

Hypertriglyceridemia refers to an elevated level of triglycerides (a type of lipid) in the bloodstream, a condition that increases the risk of coronary artery disease. The triglycerides found in ...

The late-stage results come in advance of pivotal data that Ionis expects to provide for its antisense oligonucleotide ...

One common inherited condition is called familial hypertriglyceridemia. You can also have high triglycerides for other reasons, especially if you're overweight, have an unhealthy diet, and aren't ...

Mammoth Biosciences Inc. has nominated its first clinical development candidate – MB-111 – a potential one-time treatment for patients with very high triglycerides, including familial chylomicronemia ...